Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...

Germany’s Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced research and development expenses in its healthcare segment and ...

Please visit the Merck media library for images and b-roll ... can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028. The ...

If you purchased or acquired securities in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE ... burden of retirement savings to employees, giving 401(k)s instead of pensions that promise a fixed income each ...

Merck Animal Health and AASVF awarded $50,000 in scholarships to five veterinary students pursuing careers in swine health.

About Merck At Merck, known as MSD outside of the ... statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings ...

Merck added it expects U.S. sales of Keytruda ... Sign up here. Reporting by Sneha S K in Bengaluru; Editing by Krishna Chandra Eluri The back-to-back mishaps indicate serious setbacks for a ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham ...